Research graph
References from Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015–2023. Local targets link to admitted publications; unresolved targets remain external evidence.
American Diabetes Association Professional Practice Committee for Diabetes. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
10.2337/dc26-s015 · 2026 · External reference
Global trends in prevalence of maternal overweight and obesity: a systematic review and meta-analysis of routinely collected data retrospective cohorts
2024 · External reference
Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023
10.1001/jama.2024.7112 · 2024 · External reference
GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024
2025 · External reference
Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA
10.2337/dc20-2926 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services
10.1136/bmjopen-2023-083550 · 2024 · External reference
Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy
10.1001/jamainternmed.2023.6663 · 2024 · External reference
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
10.3389/fendo.2023.1215356 · 2023 · External reference
Prescribing trends in glucagon-like peptide-1 medications among pregnant and postpartum persons
10.1097/aog.0000000000006161 · 2026 · External reference
Unresolved reference
External reference
